06torrentlogo1
Darifenacin Tablet, Extended Release
Product Images NDC 13668-202
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 13668-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
07torrentlogo2
15 mg 30 Ct Bottle Label
Darifenacin Extended-release Tablets 15 mg packaging label showing a bottle containing 30 tablets. The label includes the NDC 13668-203-30, dosing instructions, storage conditions, and manufacturer information for Torrent Pharmaceuticals Limited. The label warns to keep out of reach of children and to swallow tablets whole without chewing or crushing.*
75 mg 30 Ct Bottle Label
Darifenacin extended-release tablets 7.5 mg by Torrent Pharmaceuticals Limited, displayed on a label for a 30-tablet bottle. The label includes dosage information, storage instructions, and a barcode. The product is prescription-only, oral route, with a note to dispense accompanying patient information.*
Figure 2a Study 1
A line graph showing the median reduction and 95 percent confidence interval in incontinence episodes per week from baseline over a 12-week period. The graph compares placebo, Darifenacin 7.5 mg, and Darifenacin 15 mg, illustrating the changes at 2, 6, and 12 weeks. Darifenacin 15 mg shows the greatest reduction in episodes, followed by Darifenacin 7.5 mg, with placebo showing the least change.*
Figure 2b, Study 2
Line graph showing median reduction in incontinence episodes per week from baseline over a 12-week period, comparing placebo, Darifenacin 7.5 mg, and Darifenacin 15 mg. The x-axis represents time in weeks, while the y-axis shows median reduction with 95 percent confidence intervals. Darifenacin shows greater reduction than placebo over time.*
Figure 2c, Study 3
A line graph illustrating median reduction from baseline in weekly incontinence episodes over 12 weeks. The graph compares placebo (dashed line with open circles) and Darifenacin 15 mg (solid line with filled squares), showing greater reduction with Darifenacin. Error bars represent 95% confidence intervals for each time point.*
Figure 1
A line graph showing mean darifenacin plasma concentration (ng/mL) over 24 hours post-dose for two oral extended-release tablet strengths (7.5 mg and 15 mg). The 15 mg dose has higher plasma concentrations throughout, with error bars indicating standard deviation at each time point.*
Structure
Chemical structure diagram of darifenacin showing its molecular composition and arrangement as depicted in the image.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
